In addition, RCCEP and diarrhea were the two most common TRAEs of any grade in the IP/IC plus camrelizumab group, whereas none occurred in the EP/EC plus PD-L1 inhibitor group. The gene discussed is CD274; the disease is incontinentia pigmenti.